CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy
Top Cited Papers
- 1 April 2014
- journal article
- review article
- Published by Elsevier BV in Pharmacology & Therapeutics
- Vol. 142 (1), 1-10
- https://doi.org/10.1016/j.pharmthera.2013.10.005
Abstract
No abstract availableThis publication has 96 references indexed in Scilit:
- Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapyCell Death & Differentiation, 2011
- Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugsMolecular Oncology, 2011
- ATR signalling: more than meeting at the forkBiochemical Journal, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The DNA Damage Response: Making It Safe to Play with KnivesMolecular Cell, 2010
- The DNA-damage response in human biology and diseaseNature, 2009
- The DNA-damage effector checkpoint kinase 1 is essential for chromosome segregation and cytokinesisProceedings of the National Academy of Sciences of the United States of America, 2009
- G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancerBritish Journal of Cancer, 2008
- Chk1 regulates the density of active replication origins during the vertebrate S phaseThe EMBO Journal, 2007
- Checkpoint kinase 1 (Chk1) is required for mitotic progression through negative regulation of polo-like kinase 1 (Plk1)Proceedings of the National Academy of Sciences of the United States of America, 2006